Bremelanotide

FDA-approved melanocortin agonistEstablished

FDA-approved melanocortin agonist (Vyleesi) for acquired, generalized hypoactive sexual desire disorder in premenopausal women. 1.75 mg subcutaneous autoinjector as needed.

Calculate Dose

For research use only.

Key Facts

CAS: 189691-06-3
Molecular Weight (MW): 1025.2 g/mol
Half-life: ~2.7 hours
Unit: mcg
Administration Route: Subcutaneous
Frequency: As needed, at least 45 minutes before sexual activity
Last updated: 8/23/2026
Targets: MC4RMC3R

Overview

FDA-approved melanocortin agonist (Vyleesi) for acquired, generalized hypoactive sexual desire disorder in premenopausal women. 1.75 mg subcutaneous autoinjector as needed.

Protocol

Dosage Range: 1.75 mg per dose
Frequency: As needed, at least 45 minutes before sexual activity
Cycle: Not applicable - on-demand use
Administration Route: Subcutaneous
Reconstitution Guide: Prefilled autoinjector - no reconstitution needed

Science

Mechanism of Action

Nonselective melanocortin receptor agonist (notably MC4R) that modulates central sexual-desire pathways rather than acting as a peripheral vasodilator like PDE5 inhibitors.